181 related articles for article (PubMed ID: 21224370)
1. Primary CNS lymphoma in children and adolescents: a descriptive analysis from the International Primary CNS Lymphoma Collaborative Group (IPCG).
Abla O; Weitzman S; Blay JY; O'Neill BP; Abrey LE; Neuwelt E; Doolittle ND; Baehring J; Pradhan K; Martin SE; Guerrera M; Shah S; Ghesquieres H; Silver M; Betensky RA; Batchelor T
Clin Cancer Res; 2011 Jan; 17(2):346-52. PubMed ID: 21224370
[TBL] [Abstract][Full Text] [Related]
2. Primary CNS lymphoma of T-cell origin: a descriptive analysis from the international primary CNS lymphoma collaborative group.
Shenkier TN; Blay JY; O'Neill BP; Poortmans P; Thiel E; Jahnke K; Abrey LE; Neuwelt E; Tsang R; Batchelor T; Harris N; Ferreri AJ; Ponzoni M; O'Brien P; Rubenstein J; Connors JM
J Clin Oncol; 2005 Apr; 23(10):2233-9. PubMed ID: 15800313
[TBL] [Abstract][Full Text] [Related]
3. A prospective phase II trial of response adapted whole brain radiotherapy after high dose methotrexate based chemotherapy in patients with newly diagnosed primary central nervous system lymphoma-analysis of acute toxicity profile and early clinical outcome.
Adhikari N; Biswas A; Gogia A; Sahoo RK; Garg A; Nehra A; Sharma MC; Bhasker S; Singh M; Sreenivas V; Chawla R; Joshi G; Kumar L; Chander S
J Neurooncol; 2018 Aug; 139(1):153-166. PubMed ID: 29633112
[TBL] [Abstract][Full Text] [Related]
4. Methotrexate-cytarabine-dexamethasone combination chemotherapy with or without rituximab in patients with primary central nervous system lymphoma.
Sun X; Liu J; Wang Y; Bai X; Chen Y; Qian J; Zhu H; Liu F; Qiu X; Sun S; Ji N; Liu Y
Oncotarget; 2017 Jul; 8(30):49156-49164. PubMed ID: 28467782
[TBL] [Abstract][Full Text] [Related]
5. High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma: a prospective multicentre trial by the German Cooperative PCNSL study group.
Kasenda B; Ihorst G; Schroers R; Korfel A; Schmidt-Wolf I; Egerer G; von Baumgarten L; Röth A; Bloehdorn J; Möhle R; Binder M; Keller U; Lamprecht M; Pfreundschuh M; Valk E; Fricker H; Schorb E; Fritsch K; Finke J; Illerhaus G
Leukemia; 2017 Dec; 31(12):2623-2629. PubMed ID: 28559537
[TBL] [Abstract][Full Text] [Related]
6. Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL).
Bergner N; Monsef I; Illerhaus G; Engert A; Skoetz N
Cochrane Database Syst Rev; 2012 Nov; 11():CD009355. PubMed ID: 23152274
[TBL] [Abstract][Full Text] [Related]
7. High-dose methotrexate-based regimens and post-remission consolidation for treatment of newly diagnosed primary CNS lymphoma: meta-analysis of clinical trials.
Yu J; Du H; Ye X; Zhang L; Xiao H
Sci Rep; 2021 Jan; 11(1):2125. PubMed ID: 33483528
[TBL] [Abstract][Full Text] [Related]
8. Autologous Stem Cell Transplantation in Central Nervous System Lymphoma: A Multicenter Retrospective Series and a Review of the Literature.
Dholaria BR; Kumar A; Azzuqua AG; Nishihori T; Kharfan-Dabaja MA; Tun HW; Ayala E
Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):e273-e280. PubMed ID: 30914301
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Memorial Sloan-Kettering Cancer Center and International Extranodal Lymphoma Study Group prognostic scoring systems to predict Overall Survival in intracranial Primary CNS lymphoma.
Jahr G; Broi MD; Holte H; Beiske K; Meling TR
Brain Behav; 2018 Mar; 8(3):e00928. PubMed ID: 29541540
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of older patients with primary central nervous system lymphoma treated in routine clinical practice in the UK: methotrexate dose intensity correlates with response and survival.
Martinez-Calle N; Poynton E; Alchawaf A; Kassam S; Horan M; Rafferty M; Kelsey P; Scott G; Culligan DJ; Buckley H; Lim YJ; Ngu L; McCulloch R; Rowntree C; Wright J; McKay P; Fourali S; Eyre TA; Smith J; Osborne W; Yallop D; Linton K; Fox CP; Cwynarski K
Br J Haematol; 2020 Aug; 190(3):394-404. PubMed ID: 32232989
[TBL] [Abstract][Full Text] [Related]
11. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
[TBL] [Abstract][Full Text] [Related]
12. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial.
Thiel E; Korfel A; Martus P; Kanz L; Griesinger F; Rauch M; Röth A; Hertenstein B; von Toll T; Hundsberger T; Mergenthaler HG; Leithäuser M; Birnbaum T; Fischer L; Jahnke K; Herrlinger U; Plasswilm L; Nägele T; Pietsch T; Bamberg M; Weller M
Lancet Oncol; 2010 Nov; 11(11):1036-47. PubMed ID: 20970380
[TBL] [Abstract][Full Text] [Related]
13. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience.
Ferreri AJ; Blay JY; Reni M; Pasini F; Spina M; Ambrosetti A; Calderoni A; Rossi A; Vavassori V; Conconi A; Devizzi L; Berger F; Ponzoni M; Borisch B; Tinguely M; Cerati M; Milani M; Orvieto E; Sanchez J; Chevreau C; Dell'Oro S; Zucca E; Cavalli F
J Clin Oncol; 2003 Jan; 21(2):266-72. PubMed ID: 12525518
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy is an efficient treatment in primary CNS MALT lymphoma.
Desjardins C; Larrieu-Ciron D; Choquet S; Mokhtari K; Charlotte F; Nichelli L; Mathon B; Ahle G; Le Garff-Tavernier M; Morales-Martinez A; Dehais C; Hoang-Xuan K; Houillier C
J Neurooncol; 2022 Aug; 159(1):151-161. PubMed ID: 35725885
[TBL] [Abstract][Full Text] [Related]
15. A new prognostic score for disease progression and mortality in patients with newly diagnosed primary CNS lymphoma.
Liu CJ; Lin SY; Yang CF; Yeh CM; Kuan AS; Wang HY; Tsai CK; Gau JP; Hsiao LT; Chen PM; Liu YC; Hong YC; Ko PS; Liu JH; Lin CH
Cancer Med; 2020 Mar; 9(6):2134-2145. PubMed ID: 32011103
[TBL] [Abstract][Full Text] [Related]
16. Combined treatment with high-dose methotrexate, vincristine and procarbazine, without intrathecal chemotherapy, followed by consolidation radiotherapy for primary central nervous system lymphoma in immunocompetent patients.
Ferreri AJ; Reni M; Dell'Oro S; Ciceri F; Bernardi M; Camba L; Ponzoni M; Terreni MR; Tomirotti M; Spina M; Villa E
Oncology; 2001; 60(2):134-40. PubMed ID: 11244328
[TBL] [Abstract][Full Text] [Related]
17. [Primary central nervous system lymphoma--a report of 32 cases with literature review].
Yi JQ; Lin TY; He YJ; Huang HQ; Xia ZJ; Xia YF; Xu RH; Guo Y; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):476-80. PubMed ID: 16613684
[TBL] [Abstract][Full Text] [Related]
18. Demographics, Pattern of Care & Outcomes of Primary CNS Lymphoma- Experience from a Tertiary Care Cancer Center in India.
Das S; Bagal B; Jain H; Kashyap L; Anbarasan S; Abhishek S; Bondili S; Nayak L; Thorat J; Mirgh S; Gokarn A; Punatar S; Ayushi S; Epari S; Tembhare P; Shetty P; Khanna N; Goda J; Aliasgar M; Gupta T; Sengar M; Khattry N; Laskar S; Menon H
Indian J Hematol Blood Transfus; 2023 Jan; 39(1):57-70. PubMed ID: 36699441
[TBL] [Abstract][Full Text] [Related]
19. Role of rituximab in treatment of patients with primary central nervous system lymphoma: a retrospective analysis of the Czech lymphoma study group registry.
Mocikova H; Pytlik R; Sykorova A; Janikova A; Prochazka V; Vokurka S; Berkova A; Belada D; Campr V; Buresova L; Trneny M;
Leuk Lymphoma; 2016 Dec; 57(12):2777-2783. PubMed ID: 27087066
[TBL] [Abstract][Full Text] [Related]
20. Impact of treatment variability on survival in immuno-competent and immuno-compromised patients with primary central nervous lymphoma.
Karmali R; Nabhan C; Petrich AM; Raizer J; Peace D; Lukas R; Gordon LI; Basu S; Chukkapalli V; Venugopal P
Br J Haematol; 2017 Apr; 177(1):72-79. PubMed ID: 28211579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]